Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
Antineoplastic Combined Chemotherapy Protocols
The addition of buparlisib to carboplatin + paclitaxel was well tolerated, and preliminary activity was notable against tumors with loss of PTEN expression.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency